Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
VX

OTC · VXRT

VAXART INC

Healthcare · Biotechnology

$0.40

Up+$0.00 (+0.00%)

Updated Nov 5, 2026, 4:52 AM

SID Score

4.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
87.55M
P/E ratio
-1.65
Dividend yield
0.00%
52-week range
— – —
Volume
48.72K
Avg. volume
545.48K

Price performance · VXRT

VXRT price history

1M range · 0 trading sessions · Daily adjusted prices

VXRT does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest VXRT news

The latest Smart Investors Daily articles mentioning VXRT.

Stock researchCompany · Overview

VXRT research

Overview

Company profile and research snapshot.

Company profile

VAXART INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.00
Implied upside
—
Analysts
—
VXRT recent ratings
DateFirmRatingTarget
Mar 27, 2025B. Riley SecuritiesBuy—
Aug 15, 2024OppenheimerOutperform—
Jan 31, 2024B. Riley SecuritiesBuy—
Sep 7, 2023Cantor FitzgeraldOverweight—
Aug 7, 2023Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 8, 2026

Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model

Second-generation oral mucosal vaccine candidate (VXA-H5-02) induced robust cross-neutralizing antibodies, significantly reduced viral load, and completely protected against lethal clade 2.3.4.4b viral challenge SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines administered via tablet, today announced the publication of positive preclinical study results evaluating its adenovirus-

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By